Drug resistance of CD133+ lung cancer cells was confirmed in another study, showing that drug-resistant cells derived from NSCLC cell lines were enriched for CD133+ cells and displayed elevated cytokine expression [154]. The gene discussed is PROM1; the disease is non-small cell lung carcinoma.